ELAHERE Drug Profile

Summary for Tradename: ELAHERE

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ELAHERE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ELAHERE Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ELAHERE Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for ELAHERE

Last updated: April 14, 2026

What is ELAHERE?

ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) developed for the treatment of platinum-resistant ovarian cancer. It targets folate receptor alpha (FRα), which is overexpressed in approximately 80% of epithelial ovarian cancers. Approved by the FDA in August 2022 under accelerated approval, ELAHERE is indicated for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Market Overview

Indication and Population Size

• Approximate annual U.S. annual incidence of ovarian cancer: 20,000 cases.
• FRα-positive subset: 80% of epithelial ovarian cancers (~16,000 cases).
• Platinum-resistant subset: 60% of ovarian cancers (~12,000 cases).
• Total addressable U.S. patient population: approximately 9,600 annually.

Competitive Landscape

• Existing treatments primarily include chemotherapies, targeted agents, and immune checkpoint inhibitors.
• Bevacizumab (Avastin) has been standard, with annual sales exceeding $6 billion.
• PARP inhibitors (e.g., olaparib) target BRCA-mutated cancers but have limited efficacy in non-BRCA-mutated cases.
• Mirvetuximab was the first ADC approved specifically for this setting, targeting an unmet need.

Market Entry and Adoption

• First-mover advantage provides initial market share capture.
• Adoption impacted by clinician familiarity, regulatory updates, and real-world efficacy data.
• Competitive pipeline includes other ADCs and novel targeted therapies, potentially affecting long-term growth.

Commercial and Pricing Strategy

• List price of ELAHERE is approximately $7,600 per dose, with typical treatment consisting of four doses.
• Estimated per patient treatment cost: $30,400.
• Reimbursement depends on coverage and prior authorization, with favorable early coverage from payers.

Revenue Projections

Year	Estimated Prescriptions	Revenue (USD millions)	Assumptions
2023	4,000	122	Launch in Q3, 50% market share of initial eligible patients.
2024	8,000	244	Market expansion, increased clinician familiarity.
2025	12,000	366	Broader adoption, potential label expansion.
2026	15,000	459	Maturation, possible plateau without new indications.

Note: All figures are approximate and contingent on clinical data, reimbursement trends, and competitive dynamics.

Regulatory and Reimbursement Trajectory

• FDA granted accelerated approval based on ORR (Objective Response Rate) data from phase 2 trials.
• Confirmatory phase 3 trial (SORAYA) results expected in 2023, which could lead to full approval.
• Reimbursement hinges on positive confirmatory data and real-world evidence.
• Potential future label expansion to earlier lines of therapy or combination with other agents.

Market Barriers and Risks

• Efficacy data limited to specific populations; real-world effectiveness remains to be established.
• Competition from emerging therapies targeted at FRα or other mechanisms.
• Manufacturing and supply chain disruptions could impact availability.
• Regulatory delays or withdrawal of accelerated approval status.

Financial Trajectory Considerations

• Early revenue depends on clinician acceptance and payer coverage.
• Increased patient access and label expansion could significantly lift sales.
• Competitive pressures may restrict pricing and market share.
• Investment in post-marketing studies influences long-term sales and indication expansion.

Key Takeaways

• ELAHERE addresses a significant unmet need in platinum-resistant ovarian cancer.
• Market penetration is poised for growth, limited initially by clinician adoption and reimbursement processes.
• Revenue forecasts suggest modest growth through 2026, with high dependence on clinical outcomes and approval status.
• Competition and regulatory developments pose uncertainties to long-term financial performance.

Frequently Asked Questions

1. What is the primary mechanism of action of ELAHERE?
   It is an antibody-drug conjugate targeting folate receptor alpha, delivering a cytotoxic agent directly to FRα-expressing tumor cells.

2. How does ELAHERE compare with existing treatments?
   It offers a targeted approach for patients with limited options after platinum resistance, with an ORR of approximately 31% in trials. Compared to chemotherapy, it provides a more specific mechanism with potentially fewer side effects.

3. What are the key regulatory milestones ahead?
   The confirmatory phase 3 trial results in 2023 could lead to full FDA approval, expanding market access.

4. What market factors could limit ELAHERE’s growth?
   Competitive therapies, slow clinician uptake, payer restrictions, and potential safety concerns.

5. What is the outlook for ELAHERE’s long-term market success?
   Dependent on confirmation of efficacy, regulatory approval, label expansion, and integration into standard-of-care protocols; limited yet promising for specific patient populations.

---

Citations

[1] Food and Drug Administration. (2022). FDA approves mirvetuximab soravtansine for ovarian cancer.

[2] MarketWatch. (2023). Ovarian cancer therapeutics market analysis.

[3] ClinicalTrials.gov. (2023). SORAYA trial results.